Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria.

Daniel G K Rasmussen, Tine W Hansen, Bernt J von Scholten, Signe H Nielsen, Henrik Reinhard, Hans-Henrik Parving, Martin Tepel, Morten A Karsdal, Peter K Jacobsen, Federica Genovese, Peter Rossing

Journal: Diabetes care 2018;41(7):1493-1500

PMID: 29643059

Abstract

OBJECTIVE

Type 2 diabetes is a common risk factor for the development of chronic kidney disease (CKD). Enhanced de novo collagen type VI (COL VI) formation has been associated with renal fibrosis and CKD. We investigated the hypothesis that PRO-C6, a product specifically generated during COL VI formation, is prognostic for adverse outcomes in patients with type 2 diabetes and microalbuminuria.

RESEARCH DESIGN AND METHODS

In a prospective, observational study, we measured PRO-C6 in the serum (S-PRO-C6) and urine (U-PRO-C6) of 198 patients with type 2 diabetes and microalbuminuria without symptoms of coronary artery disease. Patients were followed for a median of 6.5 years, and end points were a composite of cardiovascular events ( = 38), all-cause mortality ( = 26), and reduction of estimated glomerular filtration rate (eGFR) of >30% (disease progression [ = 42]). Cox models were unadjusted and adjusted for the conventional risk factors of sex, age, BMI, systolic blood pressure, LDL cholesterol, smoking, HbA, plasma creatinine, and urinary albumin excretion rate.

RESULTS

Doubling of S-PRO-C6 increased hazards for cardiovascular events (hazard ratio 3.06 [95% CI 1.31-7.14]), all-cause mortality (6.91 [2.96-16.11]), and disease progression (4.81 [1.92-12.01]). Addition of S-PRO-C6 to a model containing conventional risk factors improved relative integrated discrimination by 22.5% for cardiovascular events ( = 0.02), 76.8% for all-cause mortality ( = 0.002), and 53.3% for disease progression ( = 0.004). U-PRO-C6 was not significantly associated with any of the outcomes.

CONCLUSIONS

S-PRO-C6 generated during COL VI formation predicts cardiovascular events, all-cause mortality, and disease progression in patients with type 2 diabetes and microalbuminuria.

© 2018 by the American Diabetes Association.

Address: Nordic Bioscience, Herlev, Denmark [email protected].; Institute of Molecular Medicine, Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark.; Steno Diabetes Center Copenhagen, Gentofte, Denmark.; Nordic Bioscience, Herlev, Denmark.; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.; Department of Medical Endocrinology, Rigshospitalet, Copenhagen, Denmark.; Institute of Molecular Medicine, Cardiovascular and Renal Research, University of Southern Denmark, Odense, Denmark.; Department of Nephrology, Odense University Hospital, Odense, Denmark.; Nordic Bioscience, Herlev, Denmark.; Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.; Steno Diabetes Center Copenhagen, Gentofte, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.